Table 4 Comparison of serum biomarker decreases with age.
From: Orthogonal proteomics methods warrant the development of Duchenne muscular dystrophy biomarkers
| Â | Slope | Adjusted P-values | |||
|---|---|---|---|---|---|
Biomarker candidate | Ambulant | Non-ambulant | Slope ambulant patients | Slope non-ambulant patients | Slopes difference |
CA3 | -0.1834 | -0.1235 | 0.0040 | 0.1066 | 0.7456 |
COL1A1 | -0.1506 | -0.1105 | 0.0664 | 0.2516 | 0.7456 |
FGG | -0.1883 | -0.2297 | 0.0048 | 0.0034 | 0.7456 |
LDHB | -0.1855 | -0.0507 | 0.0001 | 0.2516 | 0.0909 |
MYL3 | -0.2886 | -0.1145 | 0.0021 | 0.2516 | 0.2834 |